Efficacy of Sublingual Administration Misoprostol 600 mcg Versus 800 mcg for Induced Abortion in Women with Early Pregnancy Loss: A Randomized Controlled Trial

2021 ◽  
Vol 104 (10) ◽  
pp. 1626-1631

Objective: To compare the complete abortion rate, the induction-to-abortion time, and side effects between 600 mcg and 800 mcg misoprostol sublingually. Materials and Methods: Total, of 108 pregnant women with gestational age less than 12 weeks with early pregnancy loss from March 2020 to February 2021 at the Department of Obstetrics and Gynecology, Queen Savang Vadhana Memorial Hospital, were included. For group 1 (n=54), 600 mcg misoprostol was administrated sublingually. For group 2 (n=54), 800 mcg misoprostol was administrated sublingually. If the abortion did not occur, the repeated misoprostol in the same dose would be administrated sublingually every 6 hours for a maximum of three doses. Results: There was no significant difference in the complete abortion rate between the two groups (55.6% in the 600 mcg misoprostol group, 64.7% in the 800 mcg misoprostol group, p=0.339, and 95% CI 0.082 to 1.862). The induction-to-abortion time was 9.5 hours (IQR 6.75 to 48.00) in the 600 mcg misoprostol group and 10 hours (IQR 6.00 to 60.00) in the 800 mcg misoprostol group. The side effects of both groups were similar, included abdominal pain, diarrhea, nausea and vomiting, fever, heavy bleeding, and headache. Conclusion: The efficacy of the 600 mcg misoprostol was noninferior to 800 mcg misoprostol. The adverse effects were similar in both groups. Mean induction-to-abortion time was also similar in both groups. Keywords: Early pregnancy loss; Misoprostol; Medical abortion

2016 ◽  
Vol 48 (1-2) ◽  
pp. 7-10
Author(s):  
Eti Saha ◽  
Fouzia Begum ◽  
Zannatul Ferdous Jesmin

Early pregnancy loss is a frustrating experience for both the patient and the physician. Approximately 5% of couples trying to conceive have 2 consecutive miscarriages and approximately 1% couples have 3 or more consecutive losses. Objective of this study is to determine whether therapy with dydrogesterone or Human chorionic Gonadotrophin hormone (HCG) in history of repeated pregnancy loss during the first trimester of pregnancy will improve pregnancy outcome. This is a prospective open comparative study.Women having early pregnancy presenting to a private clinic with history of early pregnancy loss, having no medical disorder were included in this study. Eligible subjects were randomised to receive either dydrogesterone 20mg daily or injection Human Chorionic Gonadotrophins (HCG) 5000 iu intramuscularly at 72 hours interval up to fourteen weeks of pregnancy or no additional treatment. Follow up of those patients were done with transabdominal ultrasonography. Hundred women were recruited. There was no statistically significant difference between the three groups with regard to pretreatment status. The continuing pregnancy success rate was higher in women treated with dydrogesterone (79.17%) and highest with Injection Human Chorionic, Gonadotrophin (86.36%) compared with women received no treatment (70%), (p=0.358). Hormonal support with either dydrogesterone or Human Chorionic Gonadotrophin may increase the chances of a successful pregnancy in women with a history of spontaneous abortion.Bang Med J (Khulna) 2015; 48 : 7-10


Author(s):  
A.A.M. Ahmed ◽  
F.U. Ramazanova ◽  
O.B. Gigani ◽  
M.M. Azova

Background. Aneuploidy is a consequence of the chromosome nondisjunction. Majority of aneuploid embryos die in utero between the 6th and 10th week, resulting in early pregnancy loss of approximately 15% of all clinically recognized pregnancies. SYCP3 plays an important role in pairing and recombination of homologous chromosomes in meiosis I, and it has been shown that the lack of this gene leads to sterility in male and subfertility in female mice due to chromosome nondisjunction. So SYCP3 is a candidate gene to evaluate the hypothesis of fetal aneuploidy arisen from meiosis gene mutations as a cause for human early pregnancy loss. Methods. In our study, the SYCP3 T657C polymorphism in 100 Russian women with early pregnancy loss (EPL) that were classified into 2 subgroups: with sporadic pregnancy loss (SPL, n=50) and recurrent pregnancy loss (RPL, n=50), as well as 56 normal fertile women (control), was examined to determine whether there is an association between the polymorphism and early pregnancy loss in Russian population. Genomic DNA was extracted from peripheral blood samples using the standard procedure of a commercially available kit. Genotyping of SYCP3 gene was determined by allele-specific polymerase chain reaction method. Data were analyzed using SPSS statistical software version 22. The chi-square test and Fisher’s exact test were used to compare genotype and allele frequencies between analyzed groups. The odds ratio (OR) and 95% confidence intervals (CI) were used for risk estimation. Results. Frequency of the heterozygous genotype (CT) was significantly higher in the group of women with early pregnancy loss as well as in women with sporadic pregnancy loss (p<0.05). In women with RPL, we found that the frequency of this genotype tended to increase but could not make a significant difference when compared with the control group. Conclusion. Our findings postulate that the T657C polymorphism of the SYCP3 gene is possibly associated with a sporadic early pregnancy loss. Актуальность. Анеуплоидия возникает вследствие нарушения расхождения хромосом, и большинство анеуплоидных эмбрионов погибают до 10 недели гестации, что приводит к потере на ранних сроках приблизительно 15% клинически диагностированных беременностей. Белок SYCP3 играет важную роль в конъюгации и рекомбинации гомологичных хромосом в первом мейотическом делении. Было показано, что отсутствие гена данного белка у мышей приводит к стерильности самцов и снижению фертильности самок вследствие нарушения расхождения хромосом. В этой связи SYCP3 можно рассматривать в качестве кандидатного гена для оценки гипотезы о фетальной анеуплоидии, возникающей в результате мутаций генов, продукты которых участвуют в мейозе, и ведущей к ранним репродуктивным потерям. Методы. В представленной работе был исследован полиморфизм Т657С гена SYCP3 у 100 женщин русской национальности с ранними репродуктивными потерями, подразделенных на две подгруппы: со спорадической потерей беременности (n=50) и привычным невынашиванием (n=50), а также у 56 фертильных женщин (контроль). Целью работы явилось изучение наличия ассоциации между данным полиморфизмом и ранними репродуктивными потерями в русской популяции. Геномная ДНК была выделена из периферической крови, генотипирование выполнялось с использованием аллель-специфической полимеразной цепной реакции. Для сравнения частот генов и генотипов в изучаемых группах применялись критерий Хи-квадрат и точный тест Фишера, для определения которых использовалось программное обеспечение SPSS Statistics, версия 22. Оно также было использовано для расчета отношения шансов (OR) и 95% доверительного интервала. Результаты. Частота гетерозиготного генотипа СТ была достоверно выше в группе женщин с ранними репродуктивными потерями и, в частности, в подгруппе со спорадической потерей беременности (р<0,05). Несмотря на тенденцию к увеличению частоты данного генотипа у женщин с привычным невынашиванием, статистически значимых отличий от контроля обнаружено не было. Заключение. Полученные результаты позволяют предполагать наличие ассоциации между полиморфизмом Т657С гена SYCP3 и спорадической потерей беременности на ранних сроках.


1970 ◽  
Vol 25 (2) ◽  
pp. 73-76 ◽  
Author(s):  
Nilufar Sultana ◽  
Mahmuda Khatun

Objective: A randomised controlled trial was performed in Sir Solimullah Medical College Mitford Hospital, a tertiary hospital in Dhaka City for one year to compare oral misoprostol with intramascular oxytocin in the prevention of post partum haemorrhage (PPH). Method: A total of 400 women were randomised to received either 400mg misoprostol orally or 10 I.U oxytocin intramascularly. The incidence of post partum haemorrhage and side effects were examined. Result: The demographic and labour characteristic were comparable. PPH occured in 3.80% of women given misoprostol and in 2.63% of those given oxytocin (P>0.50). Measured blood loss of more than 1000 ml occured 2.38% of the misoprostol group compared with 1.58% in the oxytocin group (P>0.50). There was no significant difference in the need for additional oxytocin drugs or blood transfusion in women of both groups. Significant side effect of misoprostol were shivering (P<0.01). Conclusion: Oral misoprostol is as effective as intramascular oxytocin in the prevention of PPH. Shivering and transient pyrexia were special side effects of misoprostol. Misoprostol has potential in reducing the high incidence of PPH in developing countries. (J Bangladesh Coll Phys Surg 2007; 25 : 73-76)


2000 ◽  
Vol 79 (1) ◽  
pp. 43-48 ◽  
Author(s):  
PÉTER FEDORCSÁK ◽  
RITSA STORENG ◽  
PER OLAV DALE ◽  
TOM TANBO ◽  
THOMAS ÅBYHOLM

Sign in / Sign up

Export Citation Format

Share Document